期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

小分子化合物(EGFR-TKI)治疗非小细胞肺癌疾病进展后停药与继续原药维持的30例观察 被引量：1

下载PDF
导出
摘要 目的观察晚期非小细胞肺癌小分子化合物(EGFR-TKI)治疗既往有效,疾病进展后继续原药维持治疗较立即停药是否生存获益。方法观察30例口服小分子化合物(EGFR-TKI)治疗晚期非小细胞肺癌疾病进展后,PS评分>2分的患者,继续原小分子化合物(EGFR-TKI)维持治疗与立即停药,两组总生存(OS)。结果 30例患者,14例患者继续原小分子化合物维持,总继续生存3.5月;16例患者立即停用小分子化合物,继续生存2.9个月。结论 PS评分>2分的患者,晚期非小细胞肺癌小分子化合物(EGFR-TKI)靶向治疗疾病进展后继续原小分子化合物维持治疗生存略获益。
作者 曲进 任晓安 边吉来 唐淑红
机构地区 大连市第五人民医院 大连市胸科肿瘤研究所
出处 《当代医学》 2011年第12期107-107,共1页 Contemporary Medicine
关键词 非小细胞肺癌 小分子化合物 维持治疗 总生存期(OS)
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献4

  • 1刘晓晴,曲莉莉.晚期非小细胞肺癌EGFR-TKI失败后的治疗策略[J].临床肿瘤学杂志,2010,15(8):673-679. 被引量：6
  • 2Yokouchi H,Yamazaki K,Kinoshita l,et al. Clinical benefit ofredministration of gefiLinib for initial gefitinib responders wih non-small cell Jung cancer[J].BMC Cancer, 2007,7:51.
  • 3Riely OJ,Marks J,Pao W. KR, AS mutations in non sma, II cell lungcancer[J].PROCEEDINGS OF THE AMERfCAN THOgACIC SOCIETY(PATS),2009, 6(2):201-205.
  • 4Gregoy JPhMark qK,Bfngsheng Z,e al.Prospective assessmentof discontinuation And reinitiation of erlfowed or gefitinib followed by the Addition of evero mus[J].Olin Cance ges,2007,13(17):5150-5155.

二级参考文献23

  • 1Schiller JH, Akerley WL, Brugger W, et al. Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally ad- vanced or metastatic non-small cell lung cancer(NSCLC) [ J ]. J Clin Onco1,2010, 28 (7 Suppl) : a7502.
  • 2Wu JY, Shih JY, Yang CH, et al. Second-line treatments after first-line gefitinib therapy in advanced non-small cell lung cancer [J]. IntJCancer. 2010,126(1) :247 -255.
  • 3Chang MH, Ahn JS, Lee J, et al. The efficacy of pemetrexed as a third-or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer[J].Lung Cancer, 2010[2010-06-20]. http://www, ncbi. nlm. nih. gov/pubmed/20061047.
  • 4Yano S, Nakataki E, Ohtsuka S, et al. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases[J]. Oncol Res,2005,15(2) :107 - 111.
  • 5Oh IJ. A second round of gefitinib (Iressa) slowed disease advancement in non-small-cell lung cancer patients who failed to respond to first-line treatment[ C ]. 2010 Joint Conference on Molecular Origins in Lung Cancer, 2010: a B24.
  • 6Riely GJ, Janjigian YY, Azzoli CG, et al. Phase lI trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib [ J ]. J Clin Oncol, 2010,28 (7 Suppl) : a7557.
  • 7Shukuya T, Takahashi T, Tamiya A, et al. Gefitinib plus paclitaxel after failure of gefitinib in non-small cell lung cancer initially responding to gefitinib [ J ]. Anticancer Res, 2009, 29 (7) : 2747 - 2751.
  • 8Jackman DM, Holmes AJ, Lindeman N, et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib [ J ]. J Clin Oncol, 2006, 24 (27) :4517 -4520.
  • 9Kaira K, Naito T, Takahashi T, et al. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung eaneer[ J]. Lung Caneer, 2010,68 ( 1 ) :99 - 104.
  • 10Schiller JH, Lee JW, Hanna NH,et al. A randomized discontinuation phase H study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens: E2501[J].J Clin Oncol, 2008,26 (Suppl) : a 8014.

共引文献5

同被引文献2

引证文献1

二级引证文献4

当代医学
2011年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部